The role of inflammatory proteins in mediating the effect of cathepsins on cholelithiasis: A mendelian randomization study

Abstract

Objective

Previous studies have suggested potential associations between cathepsins and cholelithiasis. This study aimed to investigate the potential causal relationships among cathepsins, inflammatory proteins, and cholelithiasis using Mendelian randomization (MR), and to explore whether inflammatory proteins mediate the association between cathepsins and cholelithiasis.

Methods

We conducted a two-sample MR study using genome-wide association study (GWAS) summary statistics for cathepsins, inflammatory proteins, and cholelithiasis. Genetic associations for cathepsins were obtained from the INTERVAL study of European-ancestry individuals. GWAS data for inflammatory proteins and cholelithiasis were obtained from publicly available datasets, including European-ancestry cholelithiasis datasets from FinnGen and GCST90044196. The inverse variance weighted method was used as the primary MR analysis, with complementary and sensitivity analyses performed to assess the robustness of the findings. Multivariable and mediation MR analyses were performed to evaluate whether inflammatory proteins mediated the pathway from cathepsins to cholelithiasis.

Results

After correction for multiple testing, genetically predicted cathepsin B was associated with an increased risk of cholelithiasis. Mediation analyses suggested that part of the effect of cathepsin B on cholelithiasis may be mediated by fibroblast growth factor 19 (FGF19) and interleukin-6 levels. In the reverse MR analysis, genetically predicted cholelithiasis showed potential associations with two cathepsins and twelve inflammatory proteins.

Conclusions

This MR study provides genetic evidence for a potential association between cathepsin B and increased cholelithiasis risk. FGF19 and interleukin-6 may serve as partial mediators in this association.

Keywords

cathepsins cathepsin B cholelithiasis inflammatory proteins mendelian randomization mediation analysis

1. Introduction

Cholelithiasis is a common chronic digestive system disorder with an increasing incidence, contributing to a growing economic burden on society.¹ The rising prevalence of cholelithiasis has been partly attributed to changes in dietary habits, particularly increased consumption of high-calorie foods and saturated fat. In contrast, adherence to a Mediterranean dietary pattern may reduce the likelihood of cholelithiasis.¹ Anatomically, cholelithiasis can involve the intrahepatic bile ducts, hilar bile duct region, extrahepatic bile ducts, and gallbladder.² Although many patients remain asymptomatic, cholelithiasis may lead to severe complications, including pancreatitis, which can be necrotizing, hemorrhagic, and life-threatening. It may also contribute to malignant transformation in the biliary tract.³ Cholelithiasis is also closely associated with genetic susceptibility and metabolic risk factors, including obesity, dyslipidemia, and type 2 diabetes.^4,5 These considerations highlight the need to better understand the biological mechanisms underlying cholelithiasis.

Cathepsins, including serine, cysteine, or aspartic residue-based proteases, play crucial roles in a series of functions such as digestion, blood clotting, immune responses, lipid synthesis, hormone release, and peptide synthesis. However, their normal functions are fundamentally affected by the inflammatory state. Many diseases are attributed to the dysregulation of cathepsins, including arthritis, periodontitis, pancreatitis, atherosclerosis, obesity, and more.⁶ A previous study reported a 25%-50% lower activity of cathepsin L, D, and B in gallbladder mucosa of cholelithiasis patients in comparison to those without cholelithiasis.⁷ Nevertheless, further research is warranted, and the causality between cathepsins and cholelithiasis remains unclear.

Basic research results indicates that inflammation might be involved in the formation of gallstones.^8,9 Population-based studies also indicate an association between circulating inflammatory factors and the occurrence of cholelithiasis.¹⁰ Su and colleagues validated a unidirectional causal relationship between four cytokines and growth factors and cholelithiasis.¹¹ Currently, therapeutic options for cholelithiasis are limited. Exploring potential targets related to inflammatory regulation may provide useful clues for future prevention or treatment strategies for cholelithiasis.

Mendelian randomization (MR) can infer causal relationships between exposure and outcomes and is less susceptible to confounding factors.¹² In this study, we undertook a comprehensive MR analysis to investigate the causality between cathepsins, inflammatory proteins, and cholelithiasis. Subsequently, we investigated the potential role of inflammatory proteins as mediators in the pathway from cathepsins to cholelithiasis. Additionally, employing reverse causality analysis, we examined whether the genetic susceptibility to cholelithiasis risk influences the levels of cathepsins and inflammatory proteins.

2. Materials and methods

2.1. Study design

The study comprises three primary parts, as illustrated in Figure 1: the analysis of causality of 9 cathepsins on cholelithiasis (step 1A); the analysis of causality of 91 inflammatory proteins on cholelithiasis (step 2A); and the mediation analysis of inflammatory proteins in the pathway from cathepsins to cholelithiasis (step 3). Single-nucleotide polymorphisms (SNPs) were defined as instrumental variables (IVs) in this research. This MR analysis utilized data from publicly genome-wide association study (GWAS) consortia, as detailed in Table S1. The analysis relied on three fundamental assumptions: (1) the IVs are closely linked to the exposure factors; (2) IVs are not correlated with confounding factors; (3) IVs do not directly influence the outcome but only through the impact on the exposure.¹² All the studies included in the analysis had received approval from their respective ethical review boards. Furthermore, as this study solely relied on aggregated data and did not involve individual-level data, the approval of additional ethical review board was not deemed necessary.

2.2. Data source

Genetic instruments for assessing the levels of 9 cathepsins were obtained from the INTERVAL study, encompassing 3,301 European ancestry.¹³ Detailed data can be obtained at https://gwas.mrcieu.ac.uk. The data for inflammatory proteins were sourced from a prior GWAS involving 14,824 individuals, covering 91 inflammatory proteins.¹⁴ A portion of the GWAS summary data for cholelithiasis was obtained from the tenth version of the FinnGen consortium, accessible at https://www.finngen.fi/fi.¹⁵ The remaining data was obtained from the research conducted by Jiang et al., available in the GWAS Catalog database with the accession number GCST90044196 (https://www.ebi.ac.uk/gwas/).¹⁶ In the GWAS study of cholelithiasis, the FinnGen consortium had a total of 361,641 European ancestry controls and 40,191 European-ancestry cases, while the GCST90044196 study included 7,426 cases and 448,922 controls.

2.3. Instrumental variable selection

To obtain sufficient instrumental variables for each cathepsin and inflammatory protein, we adopted a relaxed threshold of P < 5 × 10^-6 for SNP selection, as only a limited number of genome-wide significant variants were available for several circulating proteins. Subsequently, SNPs demonstrating linkage disequilibrium (LD) were excluded from the analysis. For SNPs strongly associated with cholelithiasis, LD was considered acceptable if the condition r² < 0.001 within a 10,000 kb window was met.¹⁷ The exposure and outcome datasets were harmonized to align effect alleles. SNPs absent from the outcome datasets or defined as ambiguous, including palindromic SNPs with minor allele frequencies between 0.42 and 0.58, were excluded to avoid potential allele misalignment.

Relevant information, including SNP, standard error (SE), effect sizes (Beta), other allele (OA), effect allele (EA), effect allele frequency (EAF), and P-value, was extracted. Finally, we calculated F-statistic parameters and the explained variance (R²) to assess whether the identified IVs were strongly connected with the exposure. SNPs with F-statistic parameters below 10 were generally regarded as weak instruments and were subsequently removed.¹⁸ In this study, R² was computed as 2 × EAF × (1-EAF) × Beta²/(2 × EAF × (1-EAF) × Beta² + 2 × EAF × (1-EAF) × N × SE²), where N is the sample size of the GWAS, and F was calculated as R² × (N-2)/(1-R²).¹⁹

To further evaluate the potential influence of weak instrument bias, we summarized the mean, median, minimum, and maximum F-statistics of the final instrumental variables retained after LD clumping, harmonization, removal of ambiguous SNPs, and exclusion of weak instruments. We also assessed the number of available SNPs under stricter thresholds of P < 1 × 10^-6 and P < 5 × 10^-8. However, because the number of eligible SNPs was markedly reduced under these stricter thresholds, with several cathepsins retaining only one or no SNP, formal stricter-threshold multi-SNP MR sensitivity analyses were not performed.

2.4. Primary MR analysis

To assess the causal impacts of cathepsins and inflammatory proteins on cholelithiasis, we conducted two-sample MR analyses separately for step 1A and step 2A, as illustrated in Figure 1. The Inverse Variance Weighted (IVW) under a random effects model served as the primary analysis method.²⁰ Complementary analyses included the MR-Egger and Weighted Median methods. Associations were considered statistically significant when the false discovery rate (FDR)-adjusted P value of the primary IVW analysis was <0.05 and the effect estimates from the weighted median and MR-Egger analyses showed concordant directions. Estimates for each outcome from various sources were pooled using random effects meta-analysis. Results from the MR analyses were presented as odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for categorical variables and as Beta (95% CI) for continuous variables. The Benjamini-Hochberg method, controlling the FDR, was used for multiple testing correction. Associations with a nominal P < 0.05 but a Benjamini–Hochberg adjusted P > 0.05 were considered suggestive, while associations with a Benjamini–Hochberg adjusted P < 0.05 were considered significant.

2.5. Bi-directional causality analysis

To assess the bidirectional causation effect among cathepsins, inflammatory proteins, and cholelithiasis, we adopted a reverse MR analysis approach, treating cholelithiasis as the “exposure” and cathepsins and inflammatory proteins as the “outcome” (step 1B and step 2B in Figure 1). In this analysis, cholelithiasis-associated SNPs were selected as IVs using the genome-wide significance threshold of P < 5 × 10^–8. This stricter threshold was used because a sufficient number of genome-wide significant SNPs were available for cholelithiasis, which helped reduce the risk of weak instrument bias in the reverse MR analyses.

2.6. Mediation analysis

In the two-sample analysis (step 1A and step 2A in Figure 1), cathepsins and inflammatory proteins exhibiting meaningful causal impacts on cholelithiasis were selected for inclusion in the mediation analysis. Specifically, the MR effect estimates for cathepsins on each inflammatory protein were obtained using the IVW method (step 3, path a, in Figure 1). Subsequently, a multivariable MR analysis was carried out to assess the impact of inflammatory proteins on the risk of cholelithiasis while adjusting for cathepsins (step 3, path b, in Figure 1). The indirect effect was calculated by multiplying the MR estimate for the cathepsin–mediator association by the multivariable MR estimate for the mediator–cholelithiasis association. Lastly, the mediating effect was divided by the total effect to calculate the proportion of the mediating effect in the total effect (step 3, path c, in Figure 1). Mediation MR requires valid instruments that are strongly associated with the exposure, independent of confounders, and affect the outcome only through the exposure–mediator pathway. The mediated proportion was calculated as the indirect effect divided by the total effect, and all mediation estimates were calculated on the beta/log-odds scale. The 95% CIs for the mediated proportions were estimated using the delta method.

2.7. Sensitivity analysis

Cochran’s Q test was conducted to assess the heterogeneity of each SNP.²¹ Additionally, Mendelian Randomization Pleiotropy Residual Sum and Outlier (MR-PRESSO) and MR-Egger intercept were employed to examine possible horizontal pleiotropic effects. MR-PRESSO was utilized to identify notable outliers and address horizontal pleiotropy by excluding such data points.²² All analyses were conducted using R statistical software (version 4.3.1). The MR analysis was executed using the “TwoSampleMR” package. The “MR-PRESSO” package was employed to detect horizontal pleiotropy and identify outlier SNPs, and the “mediation” package was used to assess the intermediation effect.^23,24

3. Results

3.1. Causal effects of cathepsins and inflammatory proteins on cholelithiasis

Initially, we identified 133 SNPs associated with 9 cathepsins (Table S2). After harmonization and exclusion of weak instruments, 125 cathepsin SNPs were retained in the FinnGen consortium and 124 cathepsin SNPs were retained in the GCST90044196 study. In the FinnGen consortium, the overall mean and median F-statistics were 31.2 and 22.5, respectively, with a minimum F-statistic of 20.8. Similar instrument strength was observed in the GCST90044196 study. These results suggested that weak instrument bias was unlikely to substantially influence the MR estimates (Table S3). As depicted in Figure 2, genetically predicted cathepsin B was significantly associated with an increased risk of cholelithiasis after FDR correction (OR 1.06, 95% CI: 1.03 to 1.10, P = 3.01E-04; Figure 2, Table S4). The outcomes from the weighted median and MR-Egger were consistent (Table S5). MR-PRESSO identified 2 outliers in the analysis conducted in the FinnGen consortium; however, even after removing these outliers, the association persisted (Table S5).

For inflammatory proteins, we initially identified 1,817 SNPs associated with 91 inflammatory proteins (Table S6). As illustrated in Figure 3, genetically predicted fibroblast growth factor 19 (FGF19) levels were significantly associated with a decreased risk of cholelithiasis after FDR correction (OR 0.81, 95% CI: 0.72 to 0.92, P = 0.001; Tables S7 and S8). In addition, seven inflammatory proteins showed suggestive associations with cholelithiasis based on nominal significance. Delta and Notch-like epidermal growth factor-related receptor levels, leukemia inhibitory factor receptor levels, and TNF-related activation-induced cytokine levels were suggestively associated with a decreased risk of cholelithiasis, whereas C-X-C motif chemokine 10, interleukin-15 receptor subunit alpha, interleukin-6, and matrix metalloproteinase-1 were suggestively associated with an increased risk of cholelithiasis (Figure 3, Tables S7 and S8). The sensitivity analysis results demonstrated overall consistency (Table S7). Cochran’s Q test indicated SNP-level heterogeneity in 5 of the 8 inflammatory proteins. MR-Egger intercept tests indicated horizontal pleiotropy for TNF-related activation-induced cytokine levels in the FinnGen consortium but not for any other inflammatory proteins in either of the sources. MR-PRESSO identified 1–3 outliers in the analyses for FGF19 levels; nevertheless, the association persisted after removing these SNPs (Table S7). The association between FGF19 levels and cholelithiasis also remained significant after multiple comparison corrections (Table S8).

3.2. Reverse MR analysis assessing the causal impact of cholelithiasis on cathepsins and inflammatory proteins

As shown in Table S9, genetic susceptibility to cholelithiasis showed suggestive associations with higher levels of cathepsin L2 (Beta 0.07, 95% CI: 0.01 to 0.14, P = 0.022) and cathepsin O (Beta 0.09, 95% CI: 0.02 to 0.15, P = 0.006). However, these associations did not remain significant after FDR correction (Table S10).

As shown in Table S11, genetic susceptibility to cholelithiasis showed suggestive associations with increased levels of 11 inflammatory proteins, including CD40L receptor (Beta 0.04, 95% CI: 0.01 to 0.18, P = 0.017), C-X-C motif chemokine 1 (Beta 0.03, 95% CI: 0.00 to 0.06, P = 0.048), C-X-C motif chemokine 10 (Beta 0.04, 95% CI: 0.00 to 0.07, P = 0.039), C-X-C motif chemokine 11 (Beta 0.03, 95% CI: 0.00 to 0.06, P = 0.035), eotaxin (Beta 0.05, 95% CI: 0.02 to 0.08, P = 0.002), interleukin-15 receptor subunit alpha (Beta 0.04, 95% CI: 0.00 to 0.07, P = 0.038), matrix metalloproteinase-1 (Beta 0.05, 95% CI: 0.02 to 0.08, P = 0.003), monocyte chemoattractant protein-4 (Beta 0.05, 95% CI: 0.02 to 0.08, P = 0.003), programmed cell death 1 ligand 1 (PD-L1) (Beta 0.06, 95% CI: 0.03 to 0.10, P = 3.30E-04), stem cell factor (Beta 0.04, 95% CI: 0.00 to 0.08, P = 0.037) and tumor necrosis factor ligand superfamily member 12 (Beta 0.04, 95% CI: 0.01 to 0.07, P = 0.019). In addition, genetic susceptibility to cholelithiasis showed a suggestive association with decreased FGF19 levels (Beta -0.08, 95% CI: -0.14 to -0.02, P = 0.005). After FDR correction, only the association between cholelithiasis and PD-L1 levels remained significant (Table S12).

3.3. Mediation analysis

In this study, cathepsin B and eight inflammatory proteins showed potential causal associations with cholelithiasis. Demonstrating that inflammatory proteins mediate the pathway from cathepsin B to cholelithiasis requires the premise that cathepsin B was significantly associated with inflammatory proteins. Further analysis showed that genetically predicted cathepsin B was significantly associated with higher interleukin-6 levels after FDR correction and was suggestively associated with lower FGF19 levels based on nominal significance (Figure 4, Tables S13 and S14). Our multivariable MR analysis results suggested that FGF19 and interleukin-6 may serve as partial mediators in the association between cathepsin B and cholelithiasis. The cathepsin B–cholelithiasis effect was reduced from 1.06 (95% CI: 1.03 to 1.10) to 1.03 (95% CI: 0.98 to 1.08) after adjustment for FGF19 levels and to 1.04 (95% CI: 1.01 to 1.07) after adjustment for interleukin-6 levels. After simultaneous adjustment for both FGF19 and interleukin-6 levels, the effect estimate was further reduced to 0.99 (95% CI: 0.95 to 1.03) (Table 1).

Table 1.

Estimates of the mediating effects of inflammatory proteins on the association between cathepsin B and cholelithiasis.

Model	OR (95% CI)	P	Mediated proportion, % (95% CI)
MR-IVW regression, crude	1.06(1.03 to 1.10)	3.01E-04
Multivariate model
(1) Adjusted for FGF19 levels	1.03(0.98 to 1.08)	0.294	16.7 (-0.6 to 33.1)
(2) Adjusted for interleukin-6 levels	1.04(1.01 to 1.07)	0.010	1.7 (-8.9 to 12.2)
(3) Adjusted for FGF19 levels + interleukin-6 levels	0.99(0.95 to 1.03)	0.640	-

Mediated proportions were calculated on the beta/log-odds scale, and 95% CIs were estimated using the delta method. The combined mediated proportion was not calculated because the simultaneous adjustment model does not yield a directly interpretable single mediated proportion. Abbreviations: CI, confidence interval; FGF19, fibroblast growth factor 19; IVW, inverse variance weighted; MR, Mendelian randomization; OR, odds ratio.

4. Discussion

In this MR study of 9 cathepsins and 91 inflammatory proteins, genetically predicted cathepsin B was associated with an increased risk of cholelithiasis. Four inflammatory proteins showed positive associations with cholelithiasis risk, while another four showed inverse associations. Multivariable MR analyses suggested that FGF19 and interleukin-6 may partially mediate the association between cathepsin B and cholelithiasis. Intriguingly, the inverse MR analysis suggested potential effects of genetically predicted cholelithiasis on the levels of two cathepsins and twelve inflammatory proteins.

Cathepsin B is a lysosomal cysteine protease involved in lysosome-mediated cell death, protein degradation, inflammation, lipid metabolism, and tumor progression.²⁵ In this study, genetically predicted circulating cathepsin B was associated with an increased risk of cholelithiasis, which appears inconsistent with a previous observational study reporting 25%–50% lower activities of cathepsin L, D, and B in gallbladder mucosa from patients with cholelithiasis.⁷ This discrepancy may be explained by differences in tissue source, disease stage, and study design. The previous study measured local cathepsin activity in gallbladder mucosa from patients with established cholelithiasis, whereas our MR analysis evaluated the lifelong genetic predisposition to circulating cathepsin B levels. Therefore, reduced cathepsin activity in gallbladder mucosa may reflect local tissue remodeling or secondary changes after cholelithiasis development, rather than the initial causal process. Circulating cathepsin B may influence cholelithiasis through extra-gallbladder pathways, such as systemic inflammation, lipid metabolism, or biliary tract microenvironmental changes. In addition, cholelithiasis has been associated with an increased risk of biliary tract malignancies, although the magnitude and pattern of risk may vary according to the anatomical location of calculi. Mehra and colleagues demonstrated significantly elevated cathepsin B and L levels in patients with gallbladder cancer compared with controls.²⁶ Given the multifaceted roles of cathepsin B, our findings suggest that cathepsin B may represent a potential target for future studies on cholelithiasis prevention or treatment. Further studies are also needed to clarify whether cathepsin B contributes to biliary tract carcinogenesis through its potential role in cholelithiasis development.

Among the factors contributing to cholelithiasis, inflammation plays a crucial role.¹ In our MR analysis, we found that FGF19 reduces the risk of cholelithiasis, while interleukin-6 increases the risk. FGF19 is an intestinal hormone that regulates glucose, lipid, and energy balance in the body.²⁷ It also regulates bile acid homeostasis and gallbladder filling. After meals, the release of substances from food and bile increases the levels of intestinal bile acids, activating the Farnesoid X receptor (FXR) in intestinal epithelial cells. This induces the upregulation and secretion of FGF19, which enters the liver to inhibit the level of cytochrome P450 family 7 subfamily A member 1 (CYP7A1), forming a negative feedback loop to regulate bile acid synthesis.^28–30 FGF19 also relaxes gallbladder smooth muscles, promoting gallbladder filling. The interplay between FGF19 and Cholecystokinin (CCK) controls the gallbladder’s cycle of filling and emptying, as well as the flow of bile into the intestine to aid in digestion.³¹ The factors contributing to cholesterol gallstone formation may include bile composition (with cholesterol supersaturation), gallbladder motility disorders, inflammation, excessive secretion of gallbladder mucin gel, slow colon motility, and increased intestinal cholesterol absorption.³² Gallbladder emptying after meals is mainly regulated by CCK, and in patients with high triglyceride levels, there is reduced sensitivity of the gallbladder to CCK, leading to impaired gallbladder motility. This sensitivity improves after using bezafibrate or fish oil to lower serum triglyceride levels.³³ Previous studies have reported that under high-fat diet conditions, the application of recombinant FGF19 protein and FGF19 transgenic mice effectively control mouse weight by reducing fat content. These mice also show decreased concentrations of circulating triglycerides, cholesterol, and insulin in the blood, as well as decreased liver triglyceride content.³⁴ Kim and colleagues found that postprandial FGF19 and Small Heterodimer Partner (SHP) inhibit sterol regulatory element-binding transcription factor 2 (SREBF2), thereby suppressing the expression of intestinal NPC1-like intracellular cholesterol transporter 1 (NPC1L1) and cholesterol absorption.³⁵ Therefore, we hypothesize that FGF19 may reduce the risk of cholelithiasis by lowering plasma cholesterol and triglyceride concentrations. However, owing to the complete overlap of the receptor, fibroblast growth factor receptor 4 (FGFR4), in both bile acid regulation and hepatocyte proliferation, modulation of the FGF19/FGFR4 axis for diseases involving bile acid dysregulation and gallstone formation will need to be considered carefully.²⁷

Since being identified over 40 years ago as a soluble factor secreted by T cells, the interleukin-6 pathway has become a key player in health immune regulation and the dysregulation seen in various diseases.³⁶ Targeting the interleukin-6 pathway has emerged as an innovative therapeutic approach for various rheumatic diseases and cytokine release syndromes. Previous reports have also explored the relationship between interleukin-6 and cholelithiasis.¹⁰ A study utilizing a guinea pig model to explore the preventive effects of Gallbladder Emptying Granules (LDG) on gallstones indicates that LDG treatment can improve the functioning of the hypothalamus-pituitary-adrenal (HPA) axis, decrease the production of inflammatory proteins like IL-1, IL-6, and tumor necrosis factor-alpha (TNF-α) in serum, thereby preventing cholelithiasis.³⁷ Moreover, previous studies have indicated that in patients with cholelithiasis, both circulating interleukin-6 protein levels and liver interleukin-6 mRNA expression levels are elevated.^38,39 However, Ebadi and colleagues studied the gene polymorphisms of various cytokines in the bile of 254 normal individuals and 158 gallstone patients, evaluating their impact on gallstone formation, but the study did not establish a notable association between polymorphisms in TNF-α and IL-6 and the development of gallstones.⁴⁰ We speculate that the inconsistencies among these studies may be attributed to differences in the composition and function of plasma, bile, and gallbladder mucosal proteins.

The present study evaluated the potential mediating roles of FGF19 and interleukin-6 in the association between genetic predisposition to cathepsin B and cholelithiasis. Our results suggest that these two inflammatory proteins may partly mediate the effect of cathepsin B on cholelithiasis, providing genetic clues for future preventive and therapeutic exploration. However, statistical significance in MR analyses does not necessarily indicate immediate clinical applicability. Given the modest effect sizes observed in this study, the clinical relevance of these associations remains uncertain and should be evaluated in future experimental and prospective clinical studies. With the increasing application of artificial intelligence (AI) in clinical practice, AI-based models may help integrate genetic, inflammatory, metabolic, and clinical information to support individualized risk prediction and treatment strategies for patients at risk of cholelithiasis.⁴¹

In the reverse MR analysis, PD-L1 was the only inflammatory protein that remained significantly associated with genetically predicted cholelithiasis after FDR correction. This finding suggests that genetic susceptibility to cholelithiasis may be linked to increased circulating PD-L1 levels. One possible explanation is that cholelithiasis-related chronic biliary inflammation may promote immune activation and upregulation of immune checkpoint signals such as PD-L1. However, this result should be interpreted cautiously, because reverse MR reflects genetic liability rather than clinically established disease status. Further experimental and clinical studies are needed to clarify whether cholelithiasis can induce PD-L1 upregulation and to determine its potential clinical implications.

The primary robustness of the present research lies in its study design, which effectively reduces potential biases arising from reverse causality and residual confounding. Additionally, we conducted analyses using two independent data sources, and the consistency observed in results between these sources makes it less likely that the observed associations were coincidental. The exploration of mediating pathways through MVMR analysis not only enhanced mechanistic insights but also provided clues for future investigation of potential prevention strategies.

Indeed, this study has several limitations. First, although we performed multiple sensitivity analyses, the possibility of horizontal pleiotropy could not be completely excluded, as genetic variants may affect the outcome through pathways other than the exposure. Second, although all included instrumental variables had F-statistics greater than 10, the use of a relaxed threshold for instrument selection may still increase the risk of weak instrument bias. Third, the observed effect sizes were modest; therefore, the clinical significance of these associations should be interpreted cautiously. Fourth, although FGF19 and interleukin-6 may partially mediate the association between cathepsin B and cholelithiasis, the magnitude of effect reduction was modest, and the clinical significance of these mediation effects remains uncertain. In addition, the mediation analysis was based on MR assumptions and statistical decomposition of effects. Therefore, further experimental studies are needed to confirm whether FGF19 and interleukin-6 are true biological mediators in the pathway from cathepsin B to cholelithiasis. Fifth, because MR estimates reflect the lifelong effects of genetic predisposition, they may not be directly comparable with findings from observational or interventional studies. Finally, this study was mainly based on individuals of European ancestry, which may limit the generalizability of our findings to other populations. Given potential differences in genetic background, dietary patterns, and metabolic risk profiles across populations, further studies in diverse ancestries are needed to validate these associations.

5. Conclusion

This MR study provides genetic evidence for a potential causal association between cathepsin B and increased cholelithiasis risk. FGF19 and interleukin-6 may partially mediate this association. Future experimental studies and prospective clinical research are needed to validate these findings and clarify their potential value in risk assessment or therapeutic exploration.

Supplemental material

Supplemental material - The role of inflammatory proteins in mediating the effect of cathepsins on cholelithiasis: A mendelian randomization study

Supplemental material for The role of inflammatory proteins in mediating the effect of cathepsins on cholelithiasis: A mendelian randomization study by Tong Yuan and Ting Wang in Science Progress.

Footnotes

Acknowledgements

The authors express the gratitude to the referenced studies or consortia for their contribution of open-access datasets used in the analysis.

ORCID iD

Tong Yuan

Ethical considerations

This study used publicly available, de-identified GWAS summary-level data. Ethical approval and informed consent were obtained in the original studies; therefore, no additional ethical approval or informed consent was required for the present analysis.

Author contributions

Tong Yuan: Conceptualization, Formal analysis, Methodology, Writing-original draft; Ting Wang: Investigation, Validation, Writing-review & editing.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

Data described in the manuscript are provided within the article. The UKBiobank HRC-imputed can be obtained via https://pheweb.org/UKB-SAIGE/. The summary-level data for FinnGen can be obtained via .

Supplemental material

Supplemental material for this article is available online.

Appendix

References

Lammert

Gurusamy

, et al. Gallstones. Nature reviews Disease primers 2016; 2: 16024. https://doi.org/10.1038/nrdp.2016.24

Calomino

Kelmendi

Poto

, et al. The Role of Calcium Salts in Pigment Gallstones and Their Spiculated Morphology. Gastrointest Disord (Basel) 2026; 8: 2. https://doi.org/10.3390/gidisord8010002

Razumilava

Gores

. Cholangiocarcinoma. Lancet 2014; 383: 2168–2179. https://doi.org/10.1016/s0140-6736(13)61903-0

Lammert

Miquel

. Gallstone disease: from genes to evidence-based therapy. Journal of hepatology 2008; 48(Suppl 1): S124–S135. https://doi.org/10.1016/j.jhep.2008.01.012

Di Ciaula

Garruti

Frühbeck

, et al. The Role of Diet in the Pathogenesis of Cholesterol Gallstones. Current medicinal chemistry 2019; 26: 3620–3638. https://doi.org/10.2174/0929867324666170530080636

Patel

Homaei

El-Seedi

, et al. Cathepsins: Proteases that are vital for survival but can also be fatal. Biomed Pharmacother 2018; 105: 526–532. https://doi.org/10.1016/j.biopha.2018.05.148

Sahlin

Glauman

Danielsson

, et al. Lysosomal enzyme activities in gallbladder mucosa of gallstone-free subjects and patients with gallstones. Journal of hepatology 1996; 25: 895–899. https://doi.org/10.1016/s0168-8278(96)80294-7

Lei

Yan

Gao

, et al. Cholesterol crystals activate NLRP3 inflammasomes and promote gallstone formation by increasing mucin secretion. Biotechnic & histochemistry : official publication of the Biological Stain Commission 2022; 97: 546–553. https://doi.org/10.1080/10520295.2022.2036813

Muñoz

Boeltz

Bilyy

, et al. Neutrophil Extracellular Traps Initiate Gallstone Formation. Immunity 2019; 51: 443–450. https://doi.org/10.1016/j.immuni.2019.07.002

10.

Liu

Kemp

Gao

, et al. Association of circulating inflammation proteins and gallstone disease. Journal of gastroenterology and hepatology 2018; 33: 1920–1924. https://doi.org/10.1111/jgh.14265

11.

Tian

. Causal associations of cytokines and growth factors with cholelithiasis: a bidirectional Mendelian randomization study. Postgraduate medical journal 2024; 100: 84–90. https://doi.org/10.1093/postmj/qgad101

12.

Davey Smith

Hemani

. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Human molecular genetics 2014; 23: R89–R98. https://doi.org/10.1093/hmg/ddu328

13.

Sun

Maranville

Peters

, et al. Genomic atlas of the human plasma proteome. Nature 2018; 558: 73–79. https://doi.org/10.1038/s41586-018-0175-2

14.

Zhao

Stacey

Eriksson

, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 2023; 24: 1540–1551. https://doi.org/10.1038/s41590-023-01588-w

15.

Kurki

Karjalainen

Palta

, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 2023; 613: 508–518. https://doi.org/10.1038/s41586-022-05473-8

16.

Jiang

Zheng

Fang

, et al. A generalized linear mixed model association tool for biobank-scale data. Nat Genet 2021; 53: 1616–1621. https://doi.org/10.1038/s41588-021-00954-4

17.

Myers

Chanock

Machiela

. LDlinkR: An R Package for Rapidly Calculating Linkage Disequilibrium Statistics in Diverse Populations. Frontiers in genetics 2020; 11: 157. https://doi.org/10.3389/fgene.2020.00157

18.

Burgess

Small

Thompson

. A review of instrumental variable estimators for Mendelian randomization. Statistical methods in medical research 2017; 26: 2333–2355. https://doi.org/10.1177/0962280215597579

19.

Papadimitriou

Dimou

Tsilidis

, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat Commun 2020; 11: 597. https://doi.org/10.1038/s41467-020-14389-8

20.

Burgess

Butterworth

Thompson

. Mendelian randomization analysis with multiple genetic variants using summarized data. Genetic epidemiology 2013; 37: 658–665. https://doi.org/10.1002/gepi.21758

21.

Cohen

Chalumeau

Cohen

, et al. Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy. Journal of clinical epidemiology 2015; 68: 299–306. https://doi.org/10.1016/j.jclinepi.2014.09.005

22.

Verbanck

Chen

Neale

, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018; 50: 693–698. https://doi.org/10.1038/s41588-018-0099-7

23.

Ong

MacGregor

. Implementing MR-PRESSO and GCTA-GSMR for pleiotropy assessment in Mendelian randomization studies from a practitioner's perspective. Genetic epidemiology 2019; 43: 609–616. https://doi.org/10.1002/gepi.22207

24.

Tingley

Yamamoto

Hirose

, et al. mediation: R Package for Causal Mediation Analysis. Journal of Statistical Software 2014; 59: 1–38. https://doi.org/10.18637/jss.v059.i05

25.

Wang

Zheng

Yang

, et al. The Role of Cathepsin B in Pathophysiologies of Non-tumor and Tumor tissues: A Systematic Review. Journal of Cancer 2023; 14: 2344–2358. https://doi.org/10.7150/jca.86531

26.

Mehra

Kumar

Panwar

, et al. Abstract 3986: Diagnostic significance of cathepsin L and cathepsin B expression in human gallbladder cancer - A pilot study. Cancer Research 2016; 76: 3986. https://doi.org/10.1158/1538-7445.AM2016-3986

27.

Kharitonenkov

, et al. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. Journal of internal medicine 2024; 295: 292–312. https://doi.org/10.1111/joim.13767

28.

Inagaki

Choi

Moschetta

, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217–225. https://doi.org/10.1016/j.cmet.2005.09.001

29.

Holt

Luo

Billin

, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581–1591. https://doi.org/10.1101/gad.1083503

30.

Gälman

Angelin

Rudling

. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. Journal of internal medicine 2011; 270: 580–588. https://doi.org/10.1111/j.1365-2796.2011.02466.x

31.

Choi

Moschetta

Bookout

, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12: 1253–1255. https://doi.org/10.1038/nm1501

32.

Smelt

. Triglycerides and gallstone formation. Clinica chimica acta; international journal of clinical chemistry 2010; 411: 1625–1631. https://doi.org/10.1016/j.cca.2010.08.003

33.

Jonkers

Smelt

Ledeboer

, et al. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 2003; 52: 109–115. https://doi.org/10.1136/gut.52.1.109

34.

John

Adams

, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594–2603. https://doi.org/10.1210/en.2003-1671

35.

Kim

Byun

Seok

, et al. Small Heterodimer Partner and Fibroblast Growth Factor 19 Inhibit Expression of NPC1L1 in Mouse Intestine and Cholesterol Absorption. Gastroenterology 2019; 156: 1052–1065. https://doi.org/10.1053/j.gastro.2018.11.061

36.

Choy

De Benedetti

Takeuchi

, et al. Translating IL-6 biology into effective treatments. Nature reviews Rheumatology 2020; 16: 335–345. https://doi.org/10.1038/s41584-020-0419-z

37.

Liang

, et al. Prevention of gallstones by Lidan Granule: Insight into underlying mechanisms using a guinea pig model. Biomedical reports 2016; 5: 50–56. https://doi.org/10.3892/br.2016.672

38.

Shengelia

Intskirveli

Gogebashvili

. Inflammatory markers of gallstones disease in menopausal women. Georgian medical news 2012: 52–55.

39.

Fukuma

Morshed

Watanabe

, et al. Increased expression of cytokines in liver and serum in patients with extrahepatic diseases. Journal of gastroenterology 1996; 31: 538–545. https://doi.org/10.1007/bf02355054

40.

Ebadi

Daneshmandi

Ghasemi

, et al.

Cytokine single nucleotide polymorphisms in patients' with gallstone: dose TGF-β gene variants affect gallstone formation?

Molecular biology reports 2013; 40: 6256–6260. https://doi.org/10.1007/s11033-013-2737-6

41.

Malerba

Vladimirov

Goyal

, et al. Artificial Intelligence Applications in Gastric Cancer Surgery: Bridging Early Diagnosis and Responsible Precision Medicine. Journal of Clinical Medicine 2026; 15: 2208. https://doi.org/10.3390/jcm15062208

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

1.15 MB